share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024财年三季报
美股SEC公告 ·  2024/11/13 02:31

Moomoo AI 已提取核心信息

BeiGene reported Q3 2024 total revenue of $1.0 billion, up 28% year-over-year, driven by strong global BRUKINSA sales which grew 93% to $690.3 million. U.S. BRUKINSA revenue surged 87% to $503.7 million as it gained market share in CLL. Net loss narrowed to $121.4 million from $215.4 million profit last year, impacted by increased R&D and SG&A expenses.Operating expenses increased 16% to $951.4 million, with R&D expenses up 10% to $496.2 million due to advancing pipeline programs. SG&A expenses rose 25% to $455.2 million to support commercial expansion, though decreased as a percentage of product sales to 46% from 61%. Gross margin remained strong at 82.8% despite accelerated depreciation costs.The company continued global expansion with TEVIMBRA's U.S. commercial launch and positive CHMP opinions in Europe. Eight new molecular entities entered clinical development year-to-date, on track to achieve goal of 10+ by year-end. Cash position remained solid at $2.7 billion as of September 30, 2024.
BeiGene reported Q3 2024 total revenue of $1.0 billion, up 28% year-over-year, driven by strong global BRUKINSA sales which grew 93% to $690.3 million. U.S. BRUKINSA revenue surged 87% to $503.7 million as it gained market share in CLL. Net loss narrowed to $121.4 million from $215.4 million profit last year, impacted by increased R&D and SG&A expenses.Operating expenses increased 16% to $951.4 million, with R&D expenses up 10% to $496.2 million due to advancing pipeline programs. SG&A expenses rose 25% to $455.2 million to support commercial expansion, though decreased as a percentage of product sales to 46% from 61%. Gross margin remained strong at 82.8% despite accelerated depreciation costs.The company continued global expansion with TEVIMBRA's U.S. commercial launch and positive CHMP opinions in Europe. Eight new molecular entities entered clinical development year-to-date, on track to achieve goal of 10+ by year-end. Cash position remained solid at $2.7 billion as of September 30, 2024.
百济神州报告2024年第三季度总营业收入为10亿人民币，同比增长28%，主要受益于全球BRUKINSA销售的强劲增长，销售额增长93%，达到69030万人民币。美国BRUKINSA的营业收入激增87%，达到50370万人民币，市场份额在慢性淋巴细胞白血病（CLL）中不断攀升。净亏损缩小至12140万人民币，而去年为21540万人民币的利润，受研发和销售及管理费用增加的影响。营业费用增加16%，达到95140万人民币，研发费用因开发管线项目的推进上涨10%，达到49620万人民币。销售及管理费用支持商业扩展，增加25%，达到45520万人民币，但作为产品销售比例从61%下降至46%。毛利率尽管加速折旧成本依然保持强劲，达到82.8%。公司继续全球扩展，TEVIMBRA在美国的商业推广及欧洲的CHMP积极意见。迄今为止，有八个新分子实体进入临床开发，有望在年底前达到10个以上的目标。截至2024年9月30日，现金状况保持稳固，达到27亿人民币。
百济神州报告2024年第三季度总营业收入为10亿人民币，同比增长28%，主要受益于全球BRUKINSA销售的强劲增长，销售额增长93%，达到69030万人民币。美国BRUKINSA的营业收入激增87%，达到50370万人民币，市场份额在慢性淋巴细胞白血病（CLL）中不断攀升。净亏损缩小至12140万人民币，而去年为21540万人民币的利润，受研发和销售及管理费用增加的影响。营业费用增加16%，达到95140万人民币，研发费用因开发管线项目的推进上涨10%，达到49620万人民币。销售及管理费用支持商业扩展，增加25%，达到45520万人民币，但作为产品销售比例从61%下降至46%。毛利率尽管加速折旧成本依然保持强劲，达到82.8%。公司继续全球扩展，TEVIMBRA在美国的商业推广及欧洲的CHMP积极意见。迄今为止，有八个新分子实体进入临床开发，有望在年底前达到10个以上的目标。截至2024年9月30日，现金状况保持稳固，达到27亿人民币。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日